--- title: "Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/279106520.md" description: "Capricor Therapeutics (CAPR) reported a US$50.3 million loss in H1 FY 2025 with zero revenue, raising concerns about cash burn. The company's trailing twelve-month revenue is US$13.39 million, with a net loss of US$70 million. Analysts forecast a revenue growth of 37.7% annually, but current losses and high P/B ratio of 20.9x compared to industry average of 2.6x highlight execution risks. Supporters believe future earnings will improve, while critics emphasize the reliance on a single program and rising expenses." datetime: "2026-03-14T02:31:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279106520.md) - [en](https://longbridge.com/en/news/279106520.md) - [zh-HK](https://longbridge.com/zh-HK/news/279106520.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/279106520.md) | [English](https://longbridge.com/en/news/279106520.md) # Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative Capricor Therapeutics (CAPR) has just posted its FY 2025 first half results with total revenue of US$0 million and a basic EPS loss of US$1.10, while trailing twelve month revenue sits at US$13.39 million with a basic EPS loss of US$1.66. Over recent periods, the company has reported revenue of US$8.88 million and US$13.39 million across the two halves of FY 2024, alongside basic EPS losses of US$0.66 and US$0.51. This provides context for how current margins remain under pressure. With revenue still modest and losses ongoing, the focus for investors is on how quickly margins can improve from here. See our full analysis for Capricor Therapeutics. With the headline numbers on the table, the next step is to see how this earnings profile compares with the widely shared narratives around Capricor’s growth potential, risk profile, and path toward better margins. See what the community is saying about Capricor Therapeutics NasdaqGS:CAPR Earnings & Revenue History as at Mar 2026 ## US$50 million first half loss as costs climb - In the first half of FY 2025, Capricor reported a net loss of US$50.3 million on zero revenue, compared with losses of US$20.8 million and US$19.7 million on US$8.9 million and US$13.4 million of revenue in the two halves of FY 2024. - Bears point to this widening loss profile as a sign that cash burn is getting harder to ignore, especially with trailing twelve month net loss at US$70.0 million while product revenue is not yet contributing. - The bearish narrative highlights rising research and development and operating expenses, and the H1 2025 numbers align with that view by showing a much larger loss than either half of FY 2024 on a smaller revenue base. - Critics also stress Capricor’s reliance on a single main program, and the move from US$22.3 million of trailing revenue a year earlier to US$13.4 million on the latest trailing view leaves less offset to those operating costs. Stay grounded when you look at headline losses like this, and see how skeptics frame the risks around Deramiocel and cash burn in the detailed bear case for Capricor: **🐻 Capricor Therapeutics Bear Case** ## Losses widening even as forecasts point to strong growth - Over the last twelve months, Capricor generated US$13.4 million in revenue and a net loss of US$70.0 million, while analysts are forecasting revenue growth of 37.7% a year and earnings growth of about 65.8% a year with an expected move into profitability within three years. - Supporters argue this forecast profile heavily backs a bullish view that today’s losses are the price of building future earnings power, but the gap between the US$70.0 million trailing loss and the positive earnings forecast keeps execution risk front and center. - The bullish narrative leans on expectations that earnings could swing from a loss of roughly US$70.0 million today to positive earnings in the US$5.6 million to US$14.4 million range by 2028, which would be a very large shift from the current run rate. - At the same time, five year loss growth of about 30.6% per year shows that, so far, higher spending has not yet translated into improving profitability in the reported numbers, so those growth forecasts are not reflected in the recent income statement yet. If you are weighing big growth forecasts against current losses, it helps to read how bullish investors connect these numbers to their thesis on Capricor: **🐂 Capricor Therapeutics Bull Case** ## Rich valuation multiples versus peers despite DCF gap - The shares trade at a P/B of 20.9x compared with 2.6x for the US Biotechs industry, while a DCF fair value of US$312.47 per share sits far above the current price of US$30.50. - Consensus narrative commentary often points to substantial upside relative to valuation models and price targets, yet the combination of a very high P/B multiple and ongoing losses means the market is already paying a premium to book value while waiting for the projected turn to profitability. - On one side, the stock is described as trading about 90.2% below the cited DCF fair value of US$312.47, which is a very large implied upside if those cash flow assumptions are met. - On the other, trailing losses of US$70.0 million and a P/B of 20.9x compared with 2.6x for peers indicate investors today are funding a loss making business at a multiple far above the sector, which lines up with bears’ concern that valuation is demanding relative to current fundamentals. ## Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Capricor Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. With mixed views across bulls and bears, it helps to look at the numbers yourself and move quickly to shape your own view. To see how the trade off between those concerns and potential upsides stacks up in one place, check out the 3 key rewards and 2 important warning signs. ## Explore Alternatives Capricor is carrying sizeable losses, rich valuation multiples and no current product revenue, so the path to profitability and capital risk remain key concerns. If you are uneasy about that combination of cash burn and premium pricing, check out 68 resilient stocks with low risk scores to focus on companies with more resilient profiles today. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### 相關股票 - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md) - [Capricor Therap (CAPR.US)](https://longbridge.com/zh-HK/quote/CAPR.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) ## 相關資訊與研究 - [Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA | CAPR Stock News](https://longbridge.com/zh-HK/news/278565215.md) - [09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104](https://longbridge.com/zh-HK/news/281025352.md) - [Capricorn Energy Rejects Dragon Oil Bids for Western Desert Assets as Undervalued](https://longbridge.com/zh-HK/news/280347712.md) - [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/zh-HK/news/281024362.md) - [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/zh-HK/news/281026919.md)